Cancer

Aug 07, 2018

Progenics got FDA Approval on Iobenguane I 131 for Rare Adrenal Gland Tumors  A good news for unresectable rare adrenal tumor  patients as oncologists now have a new treatment to offer . On July 30, 2018, the Food and Drug Administration approved Progenics Pharmaceuticals iobenguane I for adult and pediatric patient...

Jan 09, 2018

Key to new Cancer drugs discovered in bacterial genomes Achievement is made by the scientists of The Scripps Research Institute (TSRI) Florida campus who had previously discovered LNM E1 compound used to kill prostate cancer. This time they have unlocked the capability of LNM family molecules by “mining” the in...

Dec 14, 2017

Positive Phase 2 data for Roche’s lymphoma ADC Roche’s antibody-drug conjugate for non-Hodgkin lymphoma polatuzumab has already received breakthrough designation from the USFDA and priority medicine status in the EU, and the expectations for the same are running pretty high. Phase 2 data presented by the company at...

Nov 24, 2017

Cluster of differentiation 40 or CD40 is a co-stimulatory protein found on the antigen presenting cells of the immune system. Agonistic CD40 molecules which include monoclonal antibodies (mAb) offer a new therapeutic option with the potential to generate anticancer immunity by various mechanisms. CD40 is a TNF recep...

Nov 07, 2017

Teva looks to sell generics in China through joint venture with Guangzhou Pharma As the world’s largest generics maker, Teva still doesn’t have much of a presence in China, even though it is a country relies heavily on generics. The Israeli company is looking to remedy that as Teva has said it “has no agreement with...

Nov 03, 2017

AstraZeneca and Incyte are about to enter into Clinical Trial Collaboration in Early Lung Cancer The exclusive collaboration for the study population allows the two companies to conduct a Phase 3 trial. Aim of this study is to evaluate patients with locally-advanced (Stage III), unresectable non-small cell lung c...

Sep 11, 2017

Histone deacetylase ( HDAC ) inhibitors are a new class of anti-cancer agents which play important roles in epigenetic or non-epigenetic regulation, including programmed cell death, and cell cycle arrest in cancer cells. Histone deacetylase inhibitors are either naturally occurring or they can be synthetically produ...

Sep 05, 2017

Cancer by Numbers provide us with the degree of devastation it has incurred among various populations, and provides us with a better idea on the level of progress needed to eradicate this morbid indication. It also sheds light on the blockbuster drugs along with potential therapies for the cancer. Click Here For Do...

Aug 25, 2017

Can-Fite Receives Milestone Payment from Korean Distribution Partner CKD Pharmaceuticals Can-Fite BioPharma Ltd., A Leading Biotechnology Company in the pharmaceutical industry advancing a pipeline of proprietary drugs that address various major indications related to liver, inflammatory diseases, and cancer, has an...

Aug 17, 2017

GlaxoSmithKline taps Baltimore’s Insilico for AI-based drug discovery GlaxoSmithKline and Insilico Medicine are partnering to explore how the latter’s artificial intelligence technology can aid in the drug discovery process. The duo kept mum on the details but said the agreement comes after Baltimore-based Insilico ...